Tuesday, Acusphere Inc. (ACUS), revealed positive results from additional analyses of the Phase 3 clinical trials of Imagify, an investigational new drug developed to assess perfusion using ultrasound for the detection of coronary artery disease or CAD.
The Watertown, Massachusetts-based pharmaceutical company said that the new analysis ascribed incremental predictive value to the use of Imagify for detecting coronary artery disease over other current clinical risk factors.
Acusphere expressed confidence that perfusion stress echo would have many potential benefits over nuclear stress testing including quicker results, lower cost and no exposure to radioactivity.
Sherri Oberg, President and Chief Executive Officer of Acusphere said, "We are confident that the continuing interest from clinicians for a valuable non-invasive predictive tool that helps detect coronary artery disease early on will assist us as we await approval from the U.S. Food & Drug Administration for Imagify."
Michael Picard, M.D., Director, Clinical Echocardiography at Massachusetts general hospital heart center, said the results from analysis suggested that the power to enable assessment of both wall motion and blood flow was a stronger predictor of coronary artery disease, and indeed stronger than the other clinical risk factors that most clinicians currently use.
ACUS ended Tuesday's regular trading at $0.52, down 8.77% or $0.05, on a volume of 543,670 shares on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.